Immunotherapy or targeted therapy with focused brain radiation
Treatments studied
Part of Cancer, Lungs & breathing, Skin clinical trials.
This Phase 3 study tests whether immunotherapy or targeted medicine, with or without a one-time focused brain radiation procedure, can control brain metastases from melanoma or non-small cell lung cancer. It mainly enrolls people who have no (or minimal) brain symptoms and are newly diagnosed in the brain (except for certain recent brain surgery).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old, and your general functioning is moderate to good (Karnofsky 60 or higher).
- You have melanoma or non-small cell lung cancer that has spread to the brain, confirmed by a pathology report.
- Your brain metastases are new and have not been treated before (except surgery for diagnosis).
- Your brain lesions fit the size/number limits: up to 1–10 spots, with at least one at least 5 mm; and they must not be too large overall.
- Your brain symptoms are absent or minimal (“oligo-symptomatic”); you should not need more than a stable low dose of steroid medicine for more than a week.
- You must be able to take study treatment safely: life expectancy over 12 weeks, no prior whole-brain or prior focused brain radiation, and (for this study) no prior drug treatment specifically for brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether giving immunotherapy along with a precise form of brain radiation can control brain metastases from non-small cell lung cancer. It may help by shrinking or stabilizing spots in the brain while your body’s immune system is also activated.
This study tests whether giving radiation therapy (called stereotactic radiotherapy) to the brain before or along with a combination of an experimental drug (ivonescimab) and chemotherapy can help treat non-small cell lung cancer that has spread to the brain. It compares this approach to just receiving the drug and chemotherapy without the brain radiation.
This study tests a combination of a new immunotherapy drug (ivonescimab), standard chemotherapy, and focused radiation (stereotactic radiosurgery) for non-small cell lung cancer that has spread to the brain. The goal is to see if this combination can shrink tumors in both the lungs and brain.
This trial tests a combination of a targeted immunotherapy drug (cadonilimab) with a precise type of radiation to treat brain tumors that have grown after initial lung cancer treatment. The goal is to see if this approach can safely shrink brain metastases and improve outcomes.
This trial looks at whether the timing of radiation therapy and immunotherapy (like Keytruda or Opdivo) affects outcomes in patients with non-small cell lung cancer (NSCLC) that has spread to the brain. You would receive both treatments as part of your normal care, and the study will track how you do.
This trial tests a combination of a drug that stops blood vessel growth (bevacizumab), immunotherapy, and focused radiation to treat melanoma that has spread to the brain and is causing symptoms. The goal is to see if this approach shrinks tumors and improves outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.